Journal article icon

Journal article

Inter-laboratory validation of nodal/paranodal antibody testing

Abstract:
Background and Aims
Reliable detection of antibodies against nodal targets is vital for the diagnosis of autoimmune nodopathies. The performance characteristics of recently developed in-house assays are unknown. We compared testing at four centres.
Methods
Each submitted 29–40 serum samples to a coordinating centre from one of three groups: (1) autoimmune nodopathy patients, with positive nodal/paranodal antibodies; (2) seronegative patients with other inflammatory neuropathies, and (3) healthy individuals or those with other neurological diseases. The coordinating centre recoded all samples and returned 160 identical aliquots to each testing centre for blinded testing. Once data from all centres had been received by the coordinating centre, unblinded results were returned for analysis. Sensitivity was defined by the proportion of group 1 samples returned as positive. Accuracy was defined as 0.075(sensitivity) + 0.925(specificity).
Results
Centres performed various combinations of ELISA, cell-based (CBAs) and teased-nerve fibre assays. All labs produced highly accurate results (96%–100%) and concordance for the overall result across at least 3 or all 4 test centres was observed for 98% and 89% of the samples respectively. However, 10/30 individual assays (6/14 CBAs and 4/16 ELISAs) were less than 90% sensitive. Only 3 assays had more than 1 false positive result (2 ELISAs and 1 CBA). Combining different assay modalities to produce an overall result did not improve accuracy. Inter-laboratory consistency in the determination of antibody subclasses was poor.
Interpretation
Although most samples were correctly categorised in all 4 centres, the use of a specific test modality or multiple tests did not guarantee accuracy. Early and repeated interlaboratory testing with sharing of samples is important to understand test performance and reproducibility, identify areas for improvement and maintain consistency. To aid this, we provide detailed methods for the best performing tests. Further standardisation of antibody subclass determination is required.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1111/jns.70000

Authors

More by this author
Role:
Author
ORCID:
0000-0002-9971-0584
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Clinical Neurosciences
Role:
Author


More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MR/X003922/1
MR/P008399/1


Publisher:
Wiley
Journal:
Journal of the Peripheral Nervous System More from this journal
Volume:
30
Issue:
1
Article number:
e70000
Place of publication:
United States
Publication date:
2025-01-29
Acceptance date:
2025-01-13
DOI:
EISSN:
1529-8027
ISSN:
1085-9489
Pmid:
39887819


Language:
English
Keywords:
Pubs id:
2084729
Local pid:
pubs:2084729
Deposit date:
2025-02-13
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP